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InTRoduCTIon
Antimicrobial resistance (AMR) is of increasing concern to 
global health, threatening to undermine the significant progress 
made in combating child mortality over the past two decades [1]. 
Sepsis remains an important cause of mortality in children and 
neonates – responsible for almost one-quarter of all neonatal 
deaths – with the international literature now concluding that 
up to one-third of these deaths are directly attributable to AMR 
[2]. For the treatment of sepsis in neonates, infants and children 
the World Health Organization (WHO) guidelines currently 
recommend first-line treatment with ampicillin (or penicillin) 
Abstract
Purpose. Antimicrobial resistance (AMR) is of increasing global concern, threatening to undermine recent progress in 
reducing child and neonatal mortality. Repurposing older antimicrobials is a prominent strategy to combat multidrug-
resistant sepsis. A potential agent is fosfomycin, however, there is scarce data regarding its in vitro activity and pharma-
cokinetics in the paediatric population.
Methodology. We analysed a contemporary, systematically collected archive of community-acquired (CA) and hospital-acquired 
(HA) paediatric Gram-negative bacteraemia isolates for their susceptibility to fosfomcyin. MICs were determined using agar 
serial dilution methods and validated by disk diffusion testing where breakpoints are available. Disk diffusion antimicrobial 
susceptibility testing was also conducted for current empirical therapies (ampicillin, gentamicin, ceftriaxone) and amikacin 
(proposed in the literature as a new combination empirical therapeutic option).
Results. Fosfomycin was highly active against invasive Gram-negative isolates, including 90  % (202/224) of Enterobacte-
riaceae and 96  % (22/23) of Pseudomonas spp. Fosfomycin showed high sensitivity against both CA isolates (94 %, 142/151) 
and HA isolates (81 %, 78/96; P =0.0015). CA isolates were significantly more likely to be susceptible to fosfomycin than 
the current first-line empirical therapy (96 % vs 59  %, P <0.0001). Extended spectrum β-lactamases (ESBL) production was 
detected in 34  % (85/247) of isolates with no significant difference in fosfomycin susceptibility between ESBL-positive or 
-negative isolates [73/85 (86 %) vs 147/162 (91  %) respectively, P =0.245]. All isolates were susceptible to a fosfomycin-
amikacin combination.
Conclusion. Gram-negative paediatric bacteraemia isolates are highly susceptible to fosfomycin, which could be combined 
with aminoglycosides as a new, carbapenem-sparing regimen to achieve excellent coverage to treat antimicrobial-resistant 
neonatal and paediatric sepsis.
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plus gentamicin, with third-generation cephalosporins recom-
mended as second-line therapy [3].
However, recent systematic reviews have reported high 
rates of AMR to the current regimen, documenting non-
susceptibility to penicillin/gentamicin and third-generation 
cephalosporins of 44 and 43 % (respectively) with overall 
rates of non-susceptibility to ampicillin (80 %), gentamicin 
(22 %) and ceftriaxone (74 %) among Enterobacteriaceae 
[1, 4, 5], reflecting the global emergence and spread of 
extended spectrum β-lactamases (ESBLs). Simultane-
ously, carbapenem-resistant Enterobacteriaceae (CRE) are 
responsible for an increasing number of hospital-acquired 
outbreaks and substantial morbidity and mortality [6, 7].
With a global shortage of newly discovered or effective and 
affordable alternative antibiotics available, the repurposing of 
older antimicrobials (with improved susceptibility profiles) to 
update empirical therapeutic guidelines has recently received 
increasing international attention [8]. One promising agent is 
fosfomycin, a bactericidal antibiotic that was first discovered 
in 1969. Its use was quickly overshadowed by the heavily 
promoted discovery of cephalosporins, resulting in infrequent 
international use and subsequently low global resistance 
rates [9].
The WHO has classified fosfomycin in the category of a 
‘critically important’ antimicrobial for investigation in 
light of its efficacy against multi-resistant Gram-negative 
organisms [10]; and it has been identified as an antimicro-
bial which holds great promise worldwide for managing 
MDR Gram-negative infections, due to its affordable cost 
and efficacy as a carbapenem-sparing regimen [10, 11]. 
Fosfomycin’s rapidly bactericidal activity is due to a unique 
mechanism of action of inhibition of the synthesis of pepti-
doglycan by blocking the formation of N-acetylmuramic 
acid at an earlier step than β-lactams, interfering with cell 
wall synthesis in both Gram-positive and Gram-negative 
bacteria [12]. This affords the opportunity for synergistic 
mechanisms with other antimicrobials [13, 14] and circum-
vents the resistance caused by β-lactamase-producing 
organisms, resulting in efficacy against many problematic 
pathogens such as methicillin-resistant Staphylococcus 
aureus (MRSA), glycopeptide-resistant Enterococci and 
multidrug-resistant (MDR) Enterobacteriaceae [15–17]. 
Fosfomycin is also able to penetrate biofilms, including 
those produced by vancomycin-resistant enterococci 
(VRE) [18]. However, activity against Acinetobacter 
baumannii and Burkholderia spp. and the anaerobic species 
Bacteroides is limited [17, 19].
Fosfomycin is well distributed within tissues and achieves 
clinically beneficial concentrations throughout serum, 
abscess fluid, and renal and cardiorespiratory systems 
(although it does not achieve sufficient concentrations in 
the CSF to be used as monotherapy for meningitis) [20–22]. 
Fosfomycin is not considered an appropriate empirical 
monotherapy option for sepsis due to the potential for 
the rapid emergence of resistance (and higher in vitro 
MICs observed in certain Gram-negative bacteria, such as 
Pseudomonas aeruginosa) [12]. For this reason, investiga-
tion of a broad-spectrum fosfomycin-amikacin combination 
therapy for the treatment of neonatal sepsis and meningitis is 
currently promoted in the international literature [8].
Previous research has identified fosfomycin as a relatively safe 
drug with high tolerability in children [12]. However, as fosfo-
mycin’s discovery occurred prior to the current international 
standard of drug development and approval procedures, 
significant knowledge gaps regarding its in vitro capacity 
exist. The minimal in vitro data that is available appears prom-
ising, revealing susceptibility to (predominantly urinary) 
Gram-positive and Gram-negative isolates (including ESBL-
producing E. coli and MRSA) [23, 24]. However, there is a lack 
of published evidence for the in vitro efficacy of fosfomycin 
on isolates causing bacteraemia.
With the possibility that fosfomycin may be a promising 
candidate as an empirical therapeutic regimen in neonatal 
and paediatric sepsis, its potential efficacy in a paediatric 
population is particularly important. We therefore aimed 
to address this research gap by evaluating the susceptibility 
profiles of fosfomycin in contemporary invasive Gram-nega-
tive blood isolates of a neonatal and paediatric population, 
and to analyse its susceptibility profile in comparison to the 
currently recommended empirical therapy antibiotics (ampi-
cillin, gentamicin and ceftriaxone). A second objective was to 
evaluate potential carbapenem-sparing fosfomycin-amikacin 
combination, currently under investigation as a new empirical 
therapeutic regimen for neonatal sepsis [8].
METHodS
Patients
The study examined isolates systematically collected from 
children aged 0–5 years admitted between 28 February 2012 
to 25 May 2017 to Kilifi County Hospital (KCH). KCH is a 
first-level referral hospital situated in a rural coastal region 
of Kenya, with a 35-bed paediatric ward, five-bed research 
high dependency ward and a neonatal room, which serves 
approximately 4000 patients per year. As part of the routine 
admission investigations, blood cultures are systematically 
performed on admission for all children, unless admitted 
for elective surgery or minor trauma [25]. Blood cultures 
are repeated in the case of clinical deterioration whilst 
in hospital and the date of collection recorded, allowing 
classification of cultures as either community- or hospital-
acquired infections.
Bacterial isolates
Culture and antimicrobial susceptibility testing was under-
taken at the KEMRI/Wellcome Trust Research Programme, 
which is co-located at KCH. All isolates were identified at 
the time of collection by conventional methods with confir-
mation provided by the API system (bioMérieux, Marcy 
l'Etoile, France), then stored at −80 °C in tryptic soy broth 
with 15 % glycerol. The KEMRI/Wellcome Trust laboratory 
is Good Clinical Laboratory Practice (GCLP) accredited and 
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participates in external quality assessment (including the UK 
National External Quality Assessment Service, NEQAS).
For this study, consecutive non-duplicate blood culture isolates 
were retrieved for the following Gram-negative organisms: 
Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, 
Pseudomonas aeruginosa, Pseudomonas luteola, Enterobacter 
cloacae complex, Pantoea spp., Salmonella spp., Shigella 
flexneri and Serratia marcescens. Upon retrieval, isolates 
were sub-cultured to blood agar and incubated for 18–24 h at 
37 °C in air. Isolates were classified as community-acquired 
(CA) if they were collected within 48 h of admission, or 
hospital acquired (HA) if collected beyond 48 h of admission.
Antimicrobial susceptibility testing
Fosfomycin susceptibility was determined by the agar dilu-
tion method for all isolates, and additionally by disk diffusion 
methods [for E. coli only: as described by the Clinical Labora-
tory Standards Institute (CLSI); disk diffusion breakpoints 
have not yet been validated for other Enterobacteriaceae in 
regards to fosfomycin] [26].
Disk diffusion testing was performed using Mueller–Hinton 
agar (BBL Microbiology Systems, Cockeysville MD). For 
E. coli isolates, fosfomycin disks containing 200 µg of fosfo-
mycin and 50 µg of glucose-6-phosphate (Sigma Aldrich, 
Dorset, UK) were used; for all other Enterobacteriaceae, 
disks containing amikacin (30 µg), ampicillin (10 µg), 
gentamicin (10 µg) and ceftriaxone (30 µg) (BBL Micro-
biology Systems, Cockeysville MD). E. coli ATCC 25922, 
P. aeruginosa ATCC 27953 and S. aureus ATCC 25923 were 
utilized as control strains and compared to documented 
quality control reference ranges [27]. Following overnight 
incubation in aerobic conditions at 35 °C, zone diameters 
were measured and interpreted using CLSI guidelines [27].
For susceptibility testing by agar dilution, Mueller–Hinton 
agar (BBL Microbiology Systems, Cockeysville MD) plates 
were prepared by serial dilution using fosfomycin disodium 
salt powder supplemented with 25 µg ml−1 of glucose-
6-phosphate (Sigma Aldrich, Dorset, UK) [14, 28]. For 
each isolate, 10 µl of a 0.5 ml McFarland suspension was 
inoculated on to the test plate using a transfer loop. Control 
strains, including E. coli ATCC 25922 and S. aureus ATCC 
25923 were included in each set of tests. The inoculated 
plates were incubated in aerobic conditions at 35 °C for 
18–24 h. The MIC of each antimicrobial agent was defined 
as the lowest concentration that inhibited visible growth 
of the organism.
Interpretation of susceptibility results
For the purpose of this study assessing Gram-negative bacte-
raemia, criteria for susceptibility categories by MIC were 
applied using the EUCAST interpretive criteria for all isolates 
of Enterobacteriaceae, as CLSI interpretive criteria are only 
available for urinary tract isolates of E. coli (Table 1) [27, 29]. 
For P. aeruginosa, although EUCAST/CLSI breakpoint criteria 
have not yet been established, we applied a breakpoint of 
≤64 µg ml−1 to designate susceptibility, which was inferred 
from previous evaluation on clinical isolates [30], and is 
within the EUCAST epidemiological cut-off value (ECOFF) of 
<128 µg ml−1 [31]. Breakpoints for commonly used clinical 
antibiotic therapy (ampicillin, gentamicin, ampicillin/
gentamicin combination therapy, ceftriaxone, amikacin and 
imipenem) were also analysed for isolates, which were found 
to be non-susceptible to fosfomycin (defined by EUCAST 
MIC criteria, ≥32 µg l−1).
Statistical analysis of the results was performed using STATA 
statistical software for Windows (Data Analysis and Statistical 
Software, version 15.0).
RESuLTS
A total of 247 consecutive non-duplicate archived Gram-
negative aerobic blood culture were retrieved (Table 2): 132 
isolates (53 %) from neonates (aged <28 days); 88 (36 %) 
from children aged 28 days to <2 years; and 27 (11 %) from 
children aged 2 to 5 years. Fifty-eight (23%) were isolated 
from children outside the neonatal age with severe acute 
malnutrition.
Table 1. EUCAST interpretive criteria of fosfomycin and amikacin for Enterobacteriaceae [32]
MIC (μg ml−1) Zone diameter breakpoints (mm)
Susceptible Intermediate Resistant Susceptible Intermediate Resistant
Fosfomycin ≤32 >32 ≥24* na <24*
Amikacin ≤16 32 ≥64 ≥17 15–16 ≤14
Gentamicin ≤4 8 ≥16 ≥15 13–14 ≤12
Ampicillin ≤8 16 ≥32 ≥17 14–16 ≤13
Ceftriaxone ≤1 2 ≥4 ≥23 20–22 ≤19
Imipenem ≤1 2 ≥4 ≥23 20–22 ≤19
*For E. coli only.
na, not available.
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MIC distributions – Enterobacteriaceae and 
Pseudomonas spp.
The MIC distributions of the 247 Gram-negative isolates 
are presented in Fig. 1, with analysis by species presented in 
Fig. 2. Fosfomycin was highly active against the Enterobacte-
riaceae isolates examined, with 90 % (202/224) of all isolates 
classified as sensitive (MIC ≤32 µg ml−1) as per EUCAST 
criteria. Among Pseudomonas spp., 96 % (22/23) were sensi-
tive as per the ECOFF criteria (≤64 µg ml−1) [31].
Among the Enterobacteriaceae, K. pneumoniae exhibited 
the highest frequency of non-susceptibility (20 %, 17/83), 
followed by (in order of non-susceptibility) E. coli (5 %, 
3/55) and E. cloacae (6 %, 1/17), while all Salmonella spp. and 
S. flexneri samples were fully sensitive.
Community-acquired versus hospital-acquired 
isolates
In total, 151 (61 %) isolates were CA samples while 96 
were HA (collected >48 h after admission), of which 64/96 
(67 %) were isolated from neonates. E. coli was the most 
frequently isolated CA sample (51/151, 34 %), followed by 
Klebsiella spp. (22/151, 15 %). Klebsiella spp. (n=64) were 





ESBL positive ESBL negative
Escherichia coli 56 89 % (50/56) 11 % (6/56) 14 % (8/56) 86 % (48/56)
Klebsiella spp. 87 26 % (23/87) 74 % (64/87) 78 % (68/87) 22 % (19/87)
Enterobacter cloacae complex 17 53 % (9/17) 47 % (8/17) 24 % (4/17) 76 % (13/17)
Pantoea spp. 10 70 % (7/10) 30 % (3/10) 10 % (1/10) 90 % (9/10)
Pseudomonas spp. 23 61 % (14/23) 39 % (9/23) 0 % (0/23) 100 % (23/23)
Salmonella spp. 35 91 % (32/35) 9 % (3/35) 5 % (2/35) 94 % (33/35)
Serratia marcescens 15 87 % (13/15) 13 % (2/15) 13 % (2/15) 87 % (13/15)
Shigella flexneri 3 67 % (2/3) 33 % (1/3) 0 % (0/3) 100 % (3/3)
Salmonella Typhi 1 100 % (1/1) 0 % (0/1) 0 % (0/1) 100 % (1/1)
Total 247 61 % (151/247) 39 % (96/247) 35 % (85/247) 66 % (162/247)
Fig. 1. Frequency histogram showing the number of isolates exhibiting growth at each fosfomycin agar dilution concentration level, 
identifying those classified as sensitive (MIC ≤32 µg ml−1 for Enterobacteriaceae, or ECOFF <128 µg ml−1 for Pseudomonas spp.). 
CA=community-acquired, HA=hospital-acquired.
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responsible for 67 % (64/96) of the HA isolates, followed by 
Pseudomonas spp. (n=9). HA isolates were more likely to 
exhibit fosfomycin non-susceptibility (19 %, 18/96) than CA 
isolates (6 %, 9/151, P=0.0015).
ESBL-producing isolates
Overall, 85 (34 %) of the 247 isolates tested were ESBL-
producing organisms, of which the majority (n=67, 79 %) 
were Klebsiella spp. Fosfomycin was highly active against both 
ESBL-positive and -negative isolates, revealing susceptibility 
in 91 % (147/162) of ESBL-negative isolates and 86 % (73/85) 
of ESBL-positive isolates (P=0.2).
Zone diameter interpretive criteria
Fig. 3 documents the MIC versus zone diameters for E. coli, 
illustrating high concordance between agar dilution sensi-
tivity MIC and zone diameter breakpoints by disk diffusion.
Comparison of fosfomycin susceptibility with 
currently used first-line agents
The analysis of fosfomycin susceptibility to Gram-negative 
infections for commonly used antimicrobials is presented 
in Table  3. Of 224 Enterobacteriaceae, 92 (41 %) were 
non-susceptible to the current WHO first-line therapy 
(ampicillin and gentamicin), including 16 % of CA isolates 
(24/151) and 71 % (68/96) of HA isolates. Altogether, 80 
of these 92 isolates (87 %) were susceptible to fosfomycin 
(alone), and all (100 %) were susceptible to either fosfo-
mycin or amikacin (Table 3). Similarly, of the 93 isolates 
(26 CA, 67 HA) not susceptible to ceftriaxone, 79 (85 %) 
were susceptible to fosfomycin and all (100 %) were suscep-
tible to the combination of fosfomycin and amikacin.
Fosfomycin-amikacin combination therapy
Fig. 4 illustrates the fosfomycin MIC against amikacin zone 
diameter breakpoints. All 247 Gram-negative isolates were 
sensitive to either fosfomycin or amikacin, the potential 
empirical combination therapy for neonatal sepsis [33].
Fosfomycin sensitivity and mortality
Of the 247 isolates tested 87 (35 %) were from children who 
died during that hospital admission; 47 (54 %) from neonates 
aged <28 days, with the remaining mortality cases from 
children aged <48 months. Of the 87 isolates associated with 
mortality, 42 (48 %) had community-acquired infections; 
31 % of these (13/42) were resistant to ampicillin and 
gentamicin, yet all of these isolates exhibited fosfomycin 
susceptibility.
Of the 87 isolates from children who died, 45 were 
associated with hospital-acquired infections, of which 
49 % (31/45) were non-susceptible to second-line 
therapy (ceftriaxone), yet 22 (71 %) of these resistant 
HA isolates were susceptible to fosfomycin. Overall, 
Fig. 2. Frequency histogram of the number of isolates exhibiting growth at each fosfomycin dilution level, by species. ECL=E. cloacae; 
ECO=E. coli; KPN=K. pneumonia; PSE=Pseudomonas spp.; SAL=Salmonella spp.; SFL=S. flexneri.
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there was a significantly greater proportion of fosfo-
mycin non-susceptible isolates among the children who 
died (17 %; 15/87) than among those who survived 
(7.5 %, 12/160, P=0.02).
dISCuSSIon
Fosfomycin has potential as both a new empirical thera-
peutic regimen for clinical sepsis in neonates and children 
[8] and as a carbapenem-sparing treatment strategy in MDR 
sepsis [34, 35]. In light of renewed interest in fosfomycin’s 
therapeutic potential, a range of studies have recently been 
published which acknowledge its promising in vitro activity 
[16, 32, 36–39] and our results, unique due to their presenta-
tion within clinical data, add strength to this literature.
Our analysis of 247 Gram-negative bacteremia isolates 
from children reveals high susceptibility among both 
Enterobacteriaceae and Pseudomonas spp., including MDR 
and ESBL-producing organisms, in both community- and 
hospital-acquired infections and across both neonates and 
older children. We have revealed that several Gram-negative 
invasive isolates, which were not susceptible to current 
empirical therapeutic regimens (ampicillin / gentamicin or 
ceftriaxone), were significantly more likely to be susceptible 
to fosfomycin. Our findings also revealed 100 % in vitro 
susceptibility to a combination of fosfomycin and amikacin, 
supporting the potential fosfomycin-amikacin empirical 
regimen for neonatal sepsis currently under discussion 
[8]. These two agents have the potential to provide broad-
spectrum cover with adequate penetration of the meninges, 
with a promising safety profile, whilst minimizing the likeli-
hood of resistance emerging [12]. Indeed, by circumventing 
the increasing global resistance challenges caused by ESBLs, 
this combination regimen would provide broad spectrum 
Fig. 3. Fosfomycin sensitivity of E. coli isolates, by MIC agar dilution and disk diffusion. The vertical line indicates the EUCAST breakpoint 
for Enterobacteriaceae (≤32µg ml−1). The diagonal line is the fitted linear regression.
Table 3. Proportion of Enterobacteriaceae resistant to individual antibiotics, with comparison to the likelihood of these isolates also being resistant to 
fosfomycin
Enterobacteriaceae n=224 No. of resistant 
isolates as per MIC 
testing [31]
Expressed as a % of 
isolates
No. of isolates also 
resistant to fosfomycin
(as per MIC) [31]
% Resistant to both 
antibiotics
Difference in proportions 
(P-value)
Fosfomycin 22 9.8% – – –
Gentamicin 92 41% 12 13% 28 % (P<0.001)
Amikacin 1 0.4% 0 0% 0.4 % (P>0.05)
Ampicillin 158 71% 18 11% 60 % (P<0.001)
Ceftriaxone 93 42% 14 15% 27 % (P<0.001)
Imipenem 1 0.4% 0 0% 0.4 % (P>0.05)
Ampicillin/gentamicin combination 92 41% 12 13% 28 % (P<0.001)
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carbapenem-sparing cover, with a high likelihood of improved 
clinical efficacy.
Our results have some limitations. Firstly, the isolates evalu-
ated in this study were collected from a single hospital in 
Kenya; expanding the geographic base to analyse further 
in vitro efficacy of fosfomycin would allow for improved 
generalizability. Secondly, isolates that were non-susceptible 
to fosfomycin were not sequenced to establish the mecha-
nism of resistance, which would be informative for estab-
lishing regional fosfomycin susceptibility profiles. Enzymes 
conferring fosfomycin resistance have been categorized into 
four groups – FosA, FosB, FosC and FosX. The most impor-
tant from an epidemiological point of view is FosA3 seen in 
E. coli, which is typically located on a conjugative plasmid 
that also carries the CTX-M-type ESBL – transmission of 
this plasmid-mediated resistance therefore causes both 
cephalosporin and fosfomycin resistance simultaneously 
[40]. While FosA3 was first reported in Japan in 2006, it has 
now spread across Asia in both E. coli and K. pneumoniae; 
although there are no published reports regarding its pres-
ence on other continents [41].
Our results have revealed very high susceptibility to 
fosfomycin in a range of common neonatal pathogens, 
including E. coli and K. pneumonia, and ESBL-producing 
Gram-negative infections. Furthermore, our research has 
provided a representative collection of invasive isolates due 
to the large community-acquired proportion tested, and 
importantly our analysis was broken down by the mode 
of acquisition (CA vs HA), which is commonly lacking in 
research pertaining to antimicrobial resistance [1]. Other 
strengths of this research include the generalizable popula-
tion of children from whom the isolates were drawn, the 
systematic collection of cultures on admitted children to 
our unit (removing any potential bias caused by cultures 
only being collected on the most unwell children or those 
failing initial inpatient treatment), and the susceptibility 
testing was performed in an accredited laboratory, which 
participates in international external quality assurance.
This research therefore adds valuable data regarding the 
in vitro response of Gram-negative paediatric bacteremia to 
fosfomycin, with interesting clinical outcome associations, 
including revelations on the likelihood of improved efficacy 
compared to the current levels of non-susceptibility to 
first- and second-line antimicrobial therapy in CA and HA 
infections. While the results of our data reveal promising 
susceptibility profiles for fosfomycin, more clinical research is 
required before this therapy can be recommended as empiric 
therapy in a neonatal or paediatric population. An improved 
understanding of fosfomycin’s pharmacology, pharmacody-
namics and pharmacokinetics in a neonatal and paediatric 
population is required, and randomized trials comparing the 
efficacy of the currently recommended empirical regimens 
to fosfomycin (potentially in combination with amikacin) 
are also necessary, to determine clinical efficacy and toxicity 
outcomes.
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